Aug 14, 2024, 13:00
Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer
Aditya Juloori, Radiation Oncologist at The University of Chicago Medical Center, shared on X:
“Check out our multi-center phase 2 IIT currently accruing for upfront SBRT added to Durvalumab-based chemoimmunotherapy for the first line treatment of extensive stage SCLC – the DARES trial.”
Authors: Christine M. Bestvina, Jared H. L. Hara, Theodore Karrison, Benjamen Bowar, Janet Chin, Marina C. Garassino, Sean P. Pitroda, Rajat Thawani, Everett E. Vokes, Gregory Gan, Jun Zhang, Andrew M. Baschnagel, Toby C. Campbell, Steven Chmura and Aditya Juloori.
Source: Aditya Juloori/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 18, 2024, 07:29
Sep 18, 2024, 06:44
Sep 18, 2024, 06:29
Sep 18, 2024, 06:20
Sep 18, 2024, 06:17
Sep 18, 2024, 06:12
Sep 18, 2024, 00:08
Sep 17, 2024, 22:04
Sep 17, 2024, 22:00
Sep 17, 2024, 21:57
Sep 17, 2024, 21:53